Cellular Biomedicine (NASDAQ:CBMG) target price raised to $16.00, issued a report today by Maxim Group
- Updated: September 21, 2016
Having a price of $14.33, Cellular Biomedicine (NASDAQ:CBMG) traded 0.35% higher on the day. With the last stock price down -6.97% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. CBMG has recorded a 50-day average of $14.17 and a two hundred day average of $15.40. Trade Volume was down over the average, with 14,541 shares of CBMG changing hands under the typical 33,016
Cellular Biomedicine (NASDAQ:CBMG) had its target price raised to $16.00 by Maxim Group in an issued report issued 09/22/2016. The upped price target implies a potential upside of 0.12% from the company's previous stock price.
Recent Performance Chart
Cellular Biomedicine has with a one year low of $10.44 and a one year high of $25.20 and has a market capitalization of $0.
General Company Details For Cellular Biomedicine (NASDAQ:CBMG)
Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company's technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.